Pediatric HIV treatment has been transformed by the introduction of Dolutegravir dispersible tablets, providing an effective and child-friendly treatment option.

Pediatric Formulation:
Dolutegravir 10mg dispersible tablets are specifically designed for children. These tablets disperse rapidly in water, making administration easier for young children who cannot swallow whole tablets.

Age and Weight Criteria:
Dolutegravir is approved for children weighing at least 6 kg. Weight-based dosing ensures appropriate drug levels while minimizing side effects.

Dosing Schedule:
6 to <10 kg: 15mg once daily
10 to <14 kg: 20mg once daily
14 to <20 kg: 25mg once daily
20 kg: 30-40mg once daily (depending on weight)

Clinical Evidence:
Studies have shown excellent virologic suppression rates in children treated with Dolutegravir-based regimens, comparable to adult outcomes.

Safety in Children:
Dolutegravir is generally well-tolerated in pediatric patients. Growth and development should be monitored regularly as part of standard HIV care.

Administration Tips:
Disperse the tablet in 10ml of water and administer immediately. The dispersible formulation has a pleasant strawberry flavor to improve palatability and adherence.

Importance of Adherence:
Consistent daily dosing is crucial for treatment success. Caregivers should be educated about the importance of adherence and strategies to ensure the child takes medication regularly.

WHO Recommendations:
The World Health Organization recommends Dolutegravir as a preferred option for pediatric HIV treatment, citing its efficacy, safety, and ease of administration.